This company has been acquired
ETTX Stock Overview
Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Entasis Therapeutics Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.19 |
| 52 Week High | US$3.88 |
| 52 Week Low | US$1.40 |
| Beta | 1.33 |
| 11 Month Change | 0% |
| 3 Month Change | 18.38% |
| 1 Year Change | -14.79% |
| 33 Year Change | -65.77% |
| 5 Year Change | n/a |
| Change since IPO | -79.46% |
Recent News & Updates
Recent updates
Will Entasis Therapeutics Holdings (NASDAQ:ETTX) Spend Its Cash Wisely?
Dec 16
Entasis Therapeutics: AstraZeneca Spin-Out Developing Targeted Antibacterial Products
Nov 17Is Entasis Therapeutics Holdings (NASDAQ:ETTX) In A Good Position To Invest In Growth?
Aug 19Entasis Therapeutics shares rise after lining up ETX0462 poster presentation
Jun 18What Kind Of Shareholders Own Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX)?
Feb 17
Is Entasis Therapeutics Holdings (NASDAQ:ETTX) In A Good Position To Invest In Growth?
Dec 01Shareholder Returns
| ETTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 4.0% | 2.0% |
| 1Y | -14.8% | 18.0% | 32.4% |
Return vs Industry: ETTX exceeded the US Biotechs industry which returned -20.2% over the past year.
Return vs Market: ETTX exceeded the US Market which returned -17.2% over the past year.
Price Volatility
| ETTX volatility | |
|---|---|
| ETTX Average Weekly Movement | 6.6% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ETTX has not had significant price volatility in the past 3 months.
Volatility Over Time: ETTX's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 51 | Manos Perros | www.entasistx.com |
Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections.
Entasis Therapeutics Holdings Inc. Fundamentals Summary
| ETTX fundamental statistics | |
|---|---|
| Market cap | US$104.80m |
| Earnings (TTM) | -US$51.70m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.0x
P/E RatioIs ETTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ETTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$51.70m |
| Earnings | -US$51.70m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.08 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 90.2% |
How did ETTX perform over the long term?
See historical performance and comparison